← Back to Clinical Trials
Recruiting NCT07587216

NCT07587216 Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07587216
Status Recruiting
Phase
Sponsor Tongji Hospital
Condition Liver Cancer (Primary and Metastatic)
Study Type OBSERVATIONAL
Enrollment 800 participants
Start Date 2026-01-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
liver resectionSystemic therapy combined with locoregional interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 800 participants in total. It began in 2026-01-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin

Eligibility Criteria

Inclusion Criteria: * Male or female aged ≥18 years at the time of signing the informed consent form * Clinically or histologically confirmed diagnosis of liver cancer * Recieving treatment and follow-up in Tongji Hospital Exclusion Criteria: \- Refuse participanting in this study

Contact & Investigator

Central Contact

Qi Cheng, M.D.

✉ chengqi@hust.edu.cn

📞 13871459541

Frequently Asked Questions

Who can join the NCT07587216 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Cancer (Primary and Metastatic). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07587216 currently recruiting?

Yes, NCT07587216 is actively recruiting participants. Contact the research team at chengqi@hust.edu.cn for enrollment information.

Where is the NCT07587216 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT07587216 clinical trial?

NCT07587216 is sponsored by Tongji Hospital. The trial plans to enroll 800 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology